Brief: Metacrine Reports Interim Results For Met642 Phase 2A Trial In Patients With NASH

Metacrine

21/10/2021 22:46

Oct 21 (Reuters) - Metacrine, Inc.  MTCR.O :
    * METACRINE REPORTS INTERIM RESULTS FOR MET642 PHASE 2A
TRIAL IN
PATIENTS WITH NASH AND ANNOUNCES A STRATEGIC RE-PRIORITIZATION
OF ITS CLINICAL DEVELOPMENT PROGRAMS
    * METACRINE - PRIORITIZING CLINICAL DEVELOPMENT EFFORT AND
RESOURCES TO ADVANCE MET642 INTO A PHASE 2 TRIAL IN IBD IN FIRST
HALF OF 2022
    * METACRINE, INC. - EXPECTS INDEPENDENT REVIEW OF MET642 TO
BE
COMPLETED BEFORE END OF 2021
    * METACRINE, INC. - CONDUCTING AN INDEPENDENT REVIEW OF
PRELIMINARY FINDINGS FROM A RECENTLY COMPLETED NINE-MONTH ANIMAL
TOXICOLOGY STUDY FOR MET642
    * METACRINE, INC. - TO HALT FUTURE DEVELOPMENT OF FXR
PROGRAM IN
NASH
    * METACRINE, INC. - DECISION WAS INFLUENCED IN PART BY A
POTENTIAL
DELAY IN CONFIRMING APPROPRIATE SAFETY MARGINS IN LONG-TERM
TOXICOLOGY WORK
    * METACRINE, INC. - MET642 WAS GENERALLY WELL-TOLERATED,
WITH NO
TREATMENT-RELATED SERIOUS ADVERSE EVENTS

Source text for Eikon:  ID:nGNX1Nnr6G 
Further company coverage:  MTCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))